Action Vor Biopharma - VOR

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

1,28

Prix Achat

0,75

Prix Vente

1,80

Volume échangé

356 236

1,265 Fourchette du Jour 1,40

0,63 Plage de 52 semaines 2,56

Cap du marché

87,902M

Clôture Veille

1,36

Ouverture

1,39

Dernière Transaction

300

1.28

(formt)

Dernière heure de transaction

Volume financier

US$ 474 771

VWAP

1,3327

Volume moyen (3 m)

806 696

Actions en circulation

68 673 612

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,76

Bénéfice par action (BPA)

-1,72

Chiffre d'affairess

Bénéfice net

-117,86M

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.vorbio.com

Siège social

Wilmington, Delaware, USA

Fondé

Vor Biopharma Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker VOR. Le dernier cours de clôture d'Vor Biopharma était de US$1,36. Au cours de la dernière année, les actions de Vor Biopharma ont été négociées dans une fourchette de prix de US$ 0,63 à US$ 2,56.

Vor Biopharma compte actuellement 68 673 612 actions en circulation. La capitalisation boursière d'Vor Biopharma est de US$93,40 million. Vor Biopharma a un ratio cours/bénéfice (ratio PE) de -0.76.

Form 8-K - Current report

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of...

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...

Form 8-K - Current report

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.35	-21.472392638	1.63	1.6747	1.28	582006	1.40036986	CS
4	0.41	47.1264367816	0.87	1.8	0.8192	1283463	1.35914105	CS
12	0.584	83.908045977	0.696	1.8	0.696	806696	1.11458108	CS
26	0.26	25.4901960784	1.02	1.8	0.63	806082	0.98251835	CS
52	-1.03	-44.5887445887	2.31	2.56	0.63	556020	1.19142316	CS
156	-7.78	-85.8719646799	9.06	9.72	0.63	277383	2.34571177	CS
260	-40.74	-96.9538315088	42.02	63.62	0.63	249586	6.08772765	CS

VOR - Frequently Asked Questions (FAQ)

What is the current Vor Biopharma share price?

The current share price of Vor Biopharma is US$ 1,28

How many Vor Biopharma shares are in issue?

Vor Biopharma has 68 673 612 shares in issue

What is the market cap of Vor Biopharma?

The market capitalisation of Vor Biopharma is USD 93,4M

What is the 1 year trading range for Vor Biopharma share price?

Vor Biopharma has traded in the range of US$ 0,63 to US$ 2,56 during the past year

What is the PE ratio of Vor Biopharma?

The price to earnings ratio of Vor Biopharma is -0,76

What is the reporting currency for Vor Biopharma?

Vor Biopharma reports financial results in USD

What is the latest annual profit for Vor Biopharma?

The latest annual profit of Vor Biopharma is USD -117,86M

What is the registered address of Vor Biopharma?

The registered address for Vor Biopharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Vor Biopharma website address?

The website address for Vor Biopharma is www.vorbio.com

Which industry sector does Vor Biopharma operate in?

Vor Biopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BTCTBTC Digital Ltd	US$ 8,2697 (73,73%)	61,45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8,80 (62,36%)	18,63M
CRKNCrown Electrokinetics Corporation	US$ 0,1235 (54,96%)	764,86M
NUKKNukkleus Inc	US$ 29,97 (45,98%)	19,09M
GSITGSI Technology	US$ 3,97 (44,36%)	87,7M
DOGZDogness International Corporation	US$ 18,23 (-58,77%)	740,45k
ORKTOrangeKloud Technology Inc	US$ 3,02 (-24,88%)	21,08M
PMAXPowell Max Ltd	US$ 0,6364 (-23,31%)	4,17M
LGCBLinkage Global Inc	US$ 0,2876 (-22,27%)	890,66k
YYAIConnexa Sports Technologies Inc	US$ 0,8299 (-20,20%)	602,48k
CRKNCrown Electrokinetics Corporation	US$ 0,1235 (54,96%)	764,86M
GCTKGlucoTrack Inc	US$ 0,0852 (15,45%)	465,22M
RIMEAlgorhythm Holdings Inc	US$ 0,0406 (-4,02%)	387,23M
TGLTreasure Global Inc	US$ 0,2459 (14,75%)	267,1M
NVDANVIDIA Corporation	US$ 137,71 (3,10%)	201,4M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vor Biopharma Inc (VOR)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Vor Biopharma Inc

VOR Dernières nouvelles

Form 8-K - Current report

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Vor Bio Announces $55.6 Million Private Placement

Form 8-K - Current report

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Vor Bio Announces $55.6 Million Private Placement

Form 8-K - Current report

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

VOR - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vor Biopharma Inc (VOR) Cours

Vor Biopharma Inc (VOR)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Vor Biopharma Inc

VOR Dernières nouvelles

VOR - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application